RECURSION PHARMACEUTICALS, INC. Shareholders' Equity
RECURSION PHARMACEUTICALS, INC. (RXRX) had Shareholders' Equity of $915.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-05
- 2026-06-30: Stockholders' Equity Attributable to Parent $915.00M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $1.02B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $1.13B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $1.05B.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $915.00M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $1.02B 10-Q · filed 2026-08-05 |
| 2025-12-31 | $1.13B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $1.05B 10-Q · filed 2025-11-05 |
| 2025-06-30 | $919.15M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $933.95M 10-Q · filed 2026-08-05 |
| 2024-12-31 | $1.03B 10-Q · filed 2026-08-05 |
| 2024-09-30 | $524.56M 10-Q · filed 2025-11-05 |
| 2024-06-30 | $584.45M 10-Q · filed 2025-11-05 |
| 2024-03-31 | $401.15M 10-Q · filed 2025-08-05 |
| 2023-12-31 | $463.44M 10-K · filed 2026-02-25 |
| 2023-09-30 | $437.97M 10-Q · filed 2024-11-06 |
| 2023-06-30 | $468.96M 10-Q · filed 2024-11-06 |
| 2023-03-31 | $430.18M 10-Q · filed 2024-08-08 |
| 2022-12-31 | $485.81M 10-K · filed 2026-02-25 |
| 2022-09-30 | $388.03M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $437.58M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $493.57M 10-Q · filed 2023-08-08 |
| 2021-12-31 | $542.94M 10-K · filed 2025-02-28 |
| 2021-09-30 | $599.03M 10-Q · filed 2022-11-08 |
| 2021-06-30 | $642.71M 10-Q · filed 2022-11-08 |
| 2021-03-31 | -$233.03M 10-Q · filed 2022-08-09 |
| 2020-12-31 | -$206.29M 10-K · filed 2024-02-29 |
| 2020-09-30 | -$182.07M 10-Q · filed 2021-11-10 |
| 2020-06-30 | -$159.44M 10-Q · filed 2021-11-10 |
| 2020-03-31 | -$141.39M 10-Q · filed 2021-08-13 |
| 2019-12-31 | -$124.27M 10-K · filed 2023-02-27 |
| 2018-12-31 | -$63.85M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |